Meeting
2020 ASCO Virtual Scientific Program
Thromboembolism (TE) in patients (pts) with bladder cancer treated with checkpoint inhibitors (CPIs).
Authors
Iris Yeong- Fung Sheng
Cleveland Clinic, Cleveland, OH
Iris Yeong- Fung Sheng , Shilpa Gupta , Chandana A. Reddy , Dana E Angelini , Pauline Funchain , Tamara A. Sussman , Joseph Sleiman , Timothy D. Gilligan , Moshe Chaim Ornstein , Alok A. Khorana
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5042)
DOI
10.1200/JCO.2020.38.15_suppl.5042
Abstract #
5042
Poster Bd #
111
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Significance of meflin-positive cancer-associated fibroblasts in predicting response to immune checkpoint inhibitors in non-small cell lung cancer.
First Author: Yuki Miyai
Poster
2024 ASCO Annual Meeting
Early combination with mycophenolate mofetil for immune-related hepatitis in patients with solid tumors treated with immune checkpoint inhibitors.
First Author: Yukiko Shimoda Igawa
Poster
2024 ASCO Genitourinary Cancers Symposium
Effect of neutrophil to lymphocyte ratio (NLR) on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in real-world setting.
First Author: David Lynn
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu